Gilead Sciences Inc. (NASDAQ:GILD) had its price objective raised by Royal Bank Of Canada from $95.00 to $105.00 in a research note issued to investors on Monday. They currently have an outperform rating on the biopharmaceutical company’s stock.
A number of other equities analysts have also recently issued reports on the company. Barclays PLC restated an overweight rating on shares of Gilead Sciences in a report on Thursday, July 28th. Bank of America Corp. restated a neutral rating and set a $100.00 price target on shares of Gilead Sciences in a report on Sunday, September 25th. Zacks Investment Research cut Gilead Sciences from a buy rating to a hold rating in a report on Thursday, July 28th. Leerink Swann set a $112.00 price target on Gilead Sciences and gave the stock a buy rating in a report on Thursday, September 22nd. Finally, RBC Capital Markets set a $105.00 price target on Gilead Sciences and gave the stock a buy rating in a report on Thursday, August 11th. Ten equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company. Gilead Sciences currently has a consensus rating of Buy and a consensus price target of $104.71.
Gilead Sciences (NASDAQ:GILD) opened at 76.21 on Monday. The company’s 50-day moving average is $79.10 and its 200-day moving average is $85.17. The firm has a market capitalization of $100.57 billion, a P/E ratio of 6.69 and a beta of 1.10. Gilead Sciences has a one year low of $76.07 and a one year high of $111.11.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The business had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. During the same period in the prior year, the business posted $3.15 earnings per share. The firm’s revenue was down 5.7% on a year-over-year basis. Equities analysts forecast that Gilead Sciences will post $11.76 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were paid a $0.47 dividend. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.47%. Gilead Sciences’s dividend payout ratio (DPR) is currently 16.56%.
In other news, Director Kevin E. Lofton sold 3,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 24th. The stock was sold at an average price of $81.97, for a total transaction of $286,895.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider John C. Martin sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $80.50, for a total value of $8,050,000.00. Following the transaction, the insider now directly owns 4,119,727 shares in the company, valued at $331,638,023.50. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of GILD. Gibraltar Capital Management Inc. boosted its position in Gilead Sciences by 34.3% in the first quarter. Gibraltar Capital Management Inc. now owns 51,890 shares of the biopharmaceutical company’s stock valued at $4,767,000 after buying an additional 13,267 shares during the period. QUANTRES ASSET MANAGEMENT Ltd acquired a new position in Gilead Sciences during the first quarter valued at about $1,038,000. V Wealth Management LLC acquired a new position in Gilead Sciences during the first quarter valued at about $2,443,000. Rhenman & Partners Asset Management AB boosted its position in Gilead Sciences by 45.2% in the first quarter. Rhenman & Partners Asset Management AB now owns 180,000 shares of the biopharmaceutical company’s stock valued at $16,535,000 after buying an additional 56,000 shares during the period. Finally, Private Trust Co. NA boosted its position in Gilead Sciences by 0.6% in the first quarter. Private Trust Co. NA now owns 25,010 shares of the biopharmaceutical company’s stock valued at $2,297,000 after buying an additional 147 shares during the period. 77.94% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences Company Profile